Jeremy Nicholson, Ph.D.

Professor Nicholson obtained his BSc from Liverpool University (1977) and his PhD from London University (1980) in Biochemistry working on the application of analytical electron microscopy and the applications of energy dispersive X Ray microanalysis in molecular toxicology and inorganic biochemistry. He was appointed Lecturer in Chemistry (Birkbeck College, London University, 1981-83) and Lecturer in Experimental Pathology at The London School of Pharmacy (1983-85) returning to Birkbeck as a Senior Lecturer in Chemistry (1985), then Reader (1989) and Professor of Biological Chemistry (1992). In 1998 he became Head of Biological Chemistry at Imperial College London, and since 2009 Head of the Department of Surgery and Cancer at Imperial where is actively developing new real-time point of care diagnostics with a large team of surgeons, critical care internists and cancer physicians. Professor Nicholson is the author of over 500 peer-reviewed papers on the development and application of novel spectroscopic and chemometric approaches to the investigation of disturbed metabolic and physico-chemical processes in disease states. His research has been recognized by awards such as: The Royal Society of Chemistry (RSC) Silver (1992) and Gold (1997) Medals for Analytical Chemistry; UK Chromatographic Society Jubilee Silver Medal (1994); Pfizer Prize for Chemical and Medicinal Technology (2002); The RSC medal for Chemical Biology (2003); the RSC Theophilus Redwood Lectureship (2008); the Pfizer Global Research Prize for Chemistry (2006); the Royal Society of Chemistry Interdisciplinary Prize (2008) and the Semelweiss-Budapest prize for Biomedicine (2010). His research interests include: biological NMR spectroscopy, novel LC-MS and chemometric approaches to bioanalysis, metabolic modelling and studies leading to the understanding the molecular basis of disease and toxic processes, and extended genome/superorganism biochemistry. Professor Nicholson currently holds honorary professorships at several Universities and is on the editorial board of numerous international science journals including Molecular Systems Biology and is an Associate Editor of the Journal of Proteome Research. He is a consultant to many pharmaceutical/healthcare companies in the UK, Europe and the USA and is a founder director of Metabometrix, an Imperial College spin-off company specializing in molecular phenotyping, clinical diagnostics and toxicological screening via metabonomics and metabolomics.